Argireline (Acetyl Hexapeptide-8)

Argireline (Acetyl hexapeptide-8; Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2; CAS 616204-22-9 or 575826-37-6 acetate; molecular weight 888.97 free peptide) is a six-residue N-acetylated, C-amidated peptide developed by the Spanish company Lipotec (now part of Lubrizol) and marketed as Argireline since 2002. The peptide sequence corresponds to the N-terminus of SNAP-25, a key SNARE complex protein that mediates synaptic vesicle fusion at the neuromuscular junction; SNAP-25 is the substrate cleaved by botulinum neurotoxin type A (Botox) at the same N-terminal region. The pharmacological argument for Argireline as a topical cosmetic ingredient is that the peptide competes with endogenous SNAP-25 for assembly into the SNARE complex, weakening neurotransmitter release at the neuromuscular junction at the application site and reducing the muscular contraction that drives expression-line formation. The mechanism is qualitatively similar to botulinum toxin but operates at substantially lower potency and through a distinct molecular mechanism (competitive SNAP-25 mimicry rather than enzymatic cleavage of endogenous SNAP-25). Topical penetration of an intact polar hexapeptide through the stratum corneum is intrinsically poor; modern Argireline formulations use liposomal encapsulation or other delivery vehicles to improve penetration. Published clinical evidence is mixed and dominated by manufacturer-sponsored studies; independent academic studies report modest reduction in expression-line depth at 30 days of twice-daily 10 percent topical application, substantially less than the effect of intramuscular botulinum toxin. The compound is sold as a cosmetic ingredient (not a regulated drug) in essentially all major cosmetic markets including the United States, EU, and East Asia. Stability of formulated solutions is moderate; solid peptide stored at refrigerated conditions has multi-year shelf life.